Drugs / FIB Grifols
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04636268 | Dec 2023 → Mar 2025 | congenital afibrinogenemia | Grifols, S.A. | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FIB Grifols | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04636268 ↗ |
| Modality | Protein / enzyme biologic | “Human Plasma-derived Fibrinogen Concentrate (FIB Grifols)” NCT04636268 ↗ |
| Route | Intravenous | “administered via slow intravenous (IV) infusion” NCT04636268 ↗ |